<DOC>
	<DOCNO>NCT01810016</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability immunogenicity Ipilimumab i.v . follow NY-ESO-1 Protein vaccine Poly-ICLC Montanide s.c. ( Arm A ) , NY-ESO-1 OLP4 vaccine Poly-ICLC Montanide s.c. ( Arm B ) , NY-ESO-1 OLP4 vaccine mixed Poly-ICLC without Montanide s.c. ( Arm C ) .</brief_summary>
	<brief_title>NY-ESO-1 Vaccine Combination With Ipilimumab Patients With Unresectable Metastatic Melanoma</brief_title>
	<detailed_description>This phase I , open-label , non-randomized study 27 patient unresectable metastatic melanoma , treatment ipilimumab indicate . Patients must evidence NY-ESO-1 LAGE-1 tumor positivity , radiologically measurable disease immune-related Response Criteria ( irRC ) , meet eligibility criterion .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients unresectable metastatic melanoma , treatment ipilimumab indicate per ipilimumab/Yervoy® package insert ( applicable US site ) product information ( applicable Australia site ) . Radiologically measurable disease immunerelated Response Criteria ( irRC ) . Tumor expression NYESO1 LAGE1 antigen IHC RTPCR , evidence seropositivity NYESO1 LAGE1 . Willingness provide least one preand postvaccination tumor biopsy sample . Expected survival least 4 month . At time day 1 study , patient must least 3 week since surgery . At time day 1 study , patient brain metastasis must asymptomatic : 1 ) least 8 week without tumor progression whole brain radiotherapy , 2 ) least 4 week since craniotomy resection stereotactic radiosurgery , 3 ) least 3 week without new brain metastasis evidence MRI ECOG performance status 02 . The following laboratory parameter must within range specify : Hemoglobin ≥ 10 g/dL , Neutrophil count ≥ 1.5 x 109/L , Lymphocyte count ≥ LLN Platelet count ≥ 80 x 109/L , Serum creatinine ≤ 2 mg/dL , Serum bilirubin ≤ 2 x ULN , AST/ALT ≤ 2 x ULN . Have inform treatment option . Age ≥ 18 year . Able willing give valid write informed consent . Any contraindication ipilimumab/Yervoy® per package insert ( applicable US site ) product information ( applicable Australia site ) . Prior exposure NYESO1 vaccine . Active autoimmune disease , symptoms condition except vitiligo , type I diabetes , treat thyroiditis , asymptomatic laboratory evidence autoimmune disease ( e.g . : +ANA , +RF , antithyroglobulin antibody ) , mild arthritis require therapy manageable NSAIDs . Unresolved immune related adverse event follow prior biological therapy . Systemic treatment high dose corticosteroid ( great Prednisone 10mg daily equivalent ) . Metastatic disease central nervous system therapeutic option , include radiotherapy , may available . Myocardial infarction , angina , congestive heart failure , cardiomyopathy , stroke transient ischemic attack , chest pain shortness breath activity , heart condition treat doctor . Other malignancy within 3 year prior entry study , except treat nonmelanoma skin cancer cervical carcinoma situ . Known immunodeficiency HIV positivity , active Hepatitis B active Hepatitis C. History severe allergic reaction vaccine unknown allergen . Other serious illness ( e.g. , serious infection require antibiotic , bleed disorder ) . Participation clinical trial involve another investigational agent within 4 week prior day 1 study . Mental impairment may compromise ability give informed consent comply requirement study . Lack availability immunological clinical followup assessment . Women breast feed pregnant evidence pregnancy test . Women childbearing potential use medically acceptable mean contraception duration study . Any condition , clinical judgment treat physician , likely prevent patient comply aspect protocol may put patient unacceptable risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>NY-ESO-1</keyword>
	<keyword>Metastatic Melanoma</keyword>
	<keyword>Ipilimumab</keyword>
	<keyword>Phase I</keyword>
	<keyword>Adjuvant</keyword>
	<keyword>Immunologic</keyword>
	<keyword>Vaccination</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Neoplasm</keyword>
</DOC>